CAR-T（CAR-T）细胞疗法在非肿瘤性疾病中的应用
Chimeric antigen receptor T (CAR-T) cell therapy in non-oncological diseases.
CAR-T（CAR-T）细胞在血液系统恶性肿瘤中的应用推动了这种免疫治疗形式的显著进展。
CELL INTELLIGENCE · 肿瘤细胞治疗研究
肿瘤细胞治疗研究
双特异性抗体 teclistamab 与 CAR-T 细胞疗法在复发/难治性多发性骨髓瘤中的疗效与安全性比较：一项回顾性评估
英文原题：Comparative efficacy and safety of bispecific antibody teclistamab versus CAR-T cell therapies in relapsed/refractory multiple myeloma: a retrospective evaluation.
查看英文原题
Comparative efficacy and safety of bispecific antibody teclistamab versus CAR-T cell therapies in relapsed/refractory multiple myeloma: a retrospective evaluation.
分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。
中文摘要
本研究比较双特异性抗体特克利单抗与CAR-T 细胞疗法治疗复发/难治性多发性骨髓瘤（RRMM）的临床疗效、安全性及成本效果，为个体化治疗提供依据。该回顾性研究纳入2024年12月至2025年5月在新乡市中心医院住院的67例RRMM患者（73例中排除6例），分为特克利单抗组（n=32）和CAR-T 组（n=35）。主要结局包括总体缓解率（ORR）和无进展生存期（PFS）；次要结局包括完全缓解率（CRR）、缓解持续时间（DOR）、微小残留病（MRD）阴性率、总生存期（OS）、不良事件（AE）、住院时间、直接医疗费用及成本效果比（CER）。
与特克利单抗组相比，CAR-T 组CRR较高（P=0.011）、ORR较高（P=0.029）、MRD阴性率较高（P=0.027），中位DOR更长［HR=3.35（1.838–6.10），P<0.001］，PFS更长［HR=4.407（1.994–9.74），P<0.001］，OS也更佳［HR=3.204（1.015–10.1），P=0.021］。但CAR-T 组细胞因子释放综合征（P=0.033）及血液学AE（P=0.040）发生率更高，住院时间更长、直接费用和CER更高（均P<0.001）。既往治疗线数是独立预后因素（P=0.036）。CAR-T 在疗效和生存结局方面优于特克利单抗，但AE和费用较高；特克利单抗安全性更佳、住院时间较短，支持临床个体化选择。
展开英文摘要原文
To compare the clinical efficacy, safety, and cost-effectiveness of bispecific antibody teclistamab and chimeric antigen receptor T-cell (CAR-T) therapy in relapsed/refractory multiple myeloma (RRMM) to guide individualized treatment. This retrospective study enrolled 67 RRMM patients (excluded 6 of 73) hospitalized at Xinxiang Central Hospital (December 2024-May 2025), divided into teclistamab (n=32) and CAR-T (n=35) groups. Primary outcomes included overall response rate (ORR) and progression-free survival (PFS).
Secondary outcomes comprised complete response rate (CRR), duration of response (DOR), minimal residual disease (MRD) negativity rate, overall survival (OS), adverse events (AEs), hospital stays, direct medical costs, and cost-effectiveness ratio (CER). The CAR-T group showed higher CRR (P=0. 011), ORR (P=0. 029), MRD negativity rate (P=0. 027), longer median DOR [HR: 3. 35 (1. 838, 6. 10), P<0. 001], PFS [HR: 4. 407 (1. 994, 9. 74), P<0. 001], and better OS (HR: 3. 204 (1. 015, 10. 1), P=0. 021) than the teclistamab group.
However, the CAR-T group had higher incidences of cytokine release syndrome (P=0. 033) and hematological AEs (P=0. 040), longer hospital stays, higher direct costs, and higher CER (all P<0. 001). Prior treatment lines were independent prognostic factors (P=0. 036). CAR-T therapy outperforms teclistamab in efficacy and survival outcomes but has higher AEs and costs. Teclistamab demonstrates superior safety and shorter hospital stays, supporting individualized clinical selection.
论文信息
- 作者
- Guo Y、Shi R
- 单位
- Department of Orthopedics, Xinxiang Central Hospital Xinxiang 453000, Henan, China.China
- 期刊
- American journal of cancer research2026
- 原文标识
- PubMed 41657784 · DOI 10.62347/YMDR2167
在 PubMed 查看 → 出版商原文（DOI） 全文 PDF（PMC）· 可下载 治疗专题与资料阅读指南 资料来源与翻译说明 报告译文或资料问题 →